Aripiprazole Tablet
Product Images NDC 60760-691

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 60760-691). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60760-691 (Aripiprazole 60760 691 30)

Aripiprazole 20 mg oral tablets label showing a quantity of 30 tablets. The label includes the NDC 60760-691-30 and states the medication is manufactured by Torrent Pharmaceuticals Ltd., India, and packaged by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. It advises to use as directed and store at controlled room temperature 15°-30°C (59°-86°F). The label includes a barcode and QR code along with various placeholder text for lot and expiration.*

FDA Label Image

Image 1 (Figure 1)

A pharmacokinetic chart titled 'The Effect of Other Drugs on Aripiprazole Pharmacokinetics' showing fold changes and 90% confidence intervals in aripiprazole exposure (AUC and Cmax) relative to reference without interacting drugs. The chart includes effects of CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs such as valproate, lithium, and lorazepam on aripiprazole levels.*

FDA Label Image

Image 2 (Figure 2)

A scatter plot titled 'The Effect of Other Drugs on Dehydro-Aripiprazole Pharmacokinetics' showing fold change and 90% confidence intervals for AUC and Cmax of Dehydro-Aripiprazole when co-administered with various drugs, including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam. The x-axis represents change relative to reference without interacting drug, ranging approximately from 0.5 to 3.0.*

FDA Label Image

Image 3 (Figure 3)

A pharmacokinetic chart titled 'The Effect of Aripiprazole on Pharmacokinetics of Other Drugs' showing fold change and 90% confidence intervals for various drugs metabolized by enzymes such as CYP2D6 and CYP2C9. The x-axis represents change relative to reference without interacting drug, ranging from 0.0 to 3.0, and the y-axis lists drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram with their pharmacokinetic parameters AUC and Cmax.*

FDA Label Image

Image 4 (Figure 4)

A pharmacokinetic chart illustrating the effect of intrinsic factors on aripiprazole, showing fold change and 90% confidence intervals for parameters AUC and Cmax across different special populations, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with a horizontal axis representing change relative to reference.*

FDA Label Image

Image 5 (Figure 5)

A pharmacokinetic chart showing the effect of intrinsic factors on Dehydro-aripiprazole, with fold change and 90% confidence intervals for AUC and Cmax. Factors include CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment, plotted as change relative to reference values.*

FDA Label Image

Fig-6 (Figure 6)

A Kaplan-Meier curve graph illustrating the cumulative proportion of patients experiencing relapse over time in a schizophrenia study. The x-axis shows days from randomization up to 182, and the y-axis shows the proportion with relapse from 0 to 1. Two lines compare aripiprazole treatment and placebo groups, with subject numbers at risk listed below the timeline.*

FDA Label Image

7 (Figure 7)

A Kaplan-Meier survival curve chart showing the cumulative proportion of patients experiencing relapse over time in days from randomization. It compares two groups: one treated with Aripiprazole and the other with placebo, with the y-axis representing the proportion with relapse and the x-axis showing days from randomization. A table below the graph indicates the number of subjects at risk at various time points.*

FDA Label Image

8 (Figure 8)

Kaplan-Meier estimation chart showing the cumulative proportion of patients with relapse to any mood event over 364 days from randomization in a bipolar study. The graph compares relapse proportions between aripiprazole and placebo groups, with subject numbers at risk provided across various time points.*

FDA Label Image

9 (Figure 9)

A line graph titled 'Least Square Means of Change from Baseline in YGTSS TTS by Week (Tourette's Disorder Study 1)' showing the change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph compares three groups: aripiprazole low dose, aripiprazole high dose, and placebo, with the y-axis representing least-squares mean change in tic scores and the x-axis representing weeks of treatment.*

FDA Label Image

Image (Mg Logo)

FDA Label Image

Logo (Pi Logo)

FDA Label Image

Description Image (Structure)

Chemical structure of aripiprazole, showing its molecular framework with chlorinated aromatic rings, piperazine, and other functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.